RecruitingNCT06301438

Dalpiciclib in HR+/HER2- ABC

Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study

Sponsor

RenJi Hospital

Enrollment

103 participants

Start Date

May 3, 2024

Study Type

OBSERVATIONAL

Conditions

Advanced Breast Cancer

Summary

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates dalpiciclib, a type of targeted cancer drug (CDK4/6 inhibitor), in people with advanced hormone receptor-positive, HER2-negative breast cancer. This combination approach is designed to stop cancer cells from dividing and growing. **You may be eligible if...** - You have been diagnosed with advanced (metastatic) breast cancer - Your breast cancer is hormone receptor-positive and HER2-negative - You are in good general health (ECOG score 0–1) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a history of immune deficiency - You have other conditions that make you unsuitable for this treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.